HCPLive
Digestive Disease Week 2014

Digestive Disease Week 2014 | DDW 2014

Digestive Disease Week is "the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery."

Conference Coverages

Triple Regimen of Direct-acting Antivirals Achieves High Sustained Virologic Response Rates in Patients with Hepatitis C
Triple Regimen of Direct-acting Antivirals Achieves High Sustained Virologic Response Rates in Patients with Hepatitis C
Results from the PEARL-II study show treatment-experienced patients with hepatitis C genotype 1b achieved SVR rates of greater than 96% when treated with a combination of ABT 450 with ritonavir, co-formulated with ombitasvir and dasabuvir, without the need for ribavirin.
Promising Results for First Pharmacologic Treatment for Celiac Disease
Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
Eluxadoline Effectively Treats Diarrhea-predominant Irritable Bowel Syndrome
Patients with IBS-D in two phase II trials of eluxadoline experienced sustained improvements in abdominal pain and bowel symptoms at 26 weeks of treatment, with mild side effects.
Research Yielding New Insights into the Emerging Therapy of Fecal Microbiota Transplant
Fecal microbiota transplants appear safe and patients tolerate them well in trials, but the evidence isn't there yet to establish overall benefit for treating ulcerative colitis.
Triple Antiviral Therapy Achieves Near 100% Response in Patients with Hepatitis C Genotype 4
An all-oral, ribavirin-free, interferon-free combination of three direct-acting antiviral agents that had achieved sustained virologic response in 92% of patients with chronic HCV genotype 1 infection has demonstrated even greater response in patients with genotype 4 infection.
Combination Treatment with Sofosbuvir plus Ledipasvir Highly Effective After Only Eight Weeks
Treatment with an 8-week regimen of combination sofosbuvir plus ledipasvir with or without ribavirin produced sustained virologic response rates (SVR) similar to those achieved with a 12-week regimen in non-cirrhotic, previously untreated, genotype 1 hepatitis C patients, according to results from the ION-3 trial.
Study Provides More Evidence that Statins Help Slow Liver Fibrosis in Hepatitis C
Patients in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial who were also treated with statins experienced a significant decrease in time to histological disease progression compared to patients who did not receive statin treatment.
Approval of Newer, More Effective Hepatitis C Drugs Means a Cure Is Within Reach for Most Patients
Within the next two years, treatments for hepatitis C with 95% cure rates that are all-oral, interferon-free, and effective within 12 weeks or less with negligible side effects will be readily available.
Promising Initial Results from Novel Treatment for Ulcerative Colitis
Phase 2 study results show patients with ulcerative colitis treated with an investigational oral compound achieved higher rates of remission, reduced rectal bleeding, and increased mucosal healing compared to patients who received placebo.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$